In Brief: Ciba-Geigy Corp.
This article was originally published in The Tan Sheet
Executive Summary
Ciba-Geigy Corp.: Richard Barth is retiring as U.S. president and CEO on March 31, to be succeeded by Ciba Pharmaceuticals President Douglas Watson. Barth, a 30-year Ciba veteran, will retain the chairman's post, which he has held since 1990. Replacing Watson as president of the pharmaceuticals division will be Senior VP-Marketing James Callahan. Once the changes become effective, Remo Denti, the new head of Ciba's U.S. OTC business ("The Tan Sheet" May 5, p. 9), will report to Watson as well as Roland Genet, head of Ciba Self-Medications worldwide...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning